Lindbrook Capital, LLC Editas Medicine, Inc. Transaction History

Lindbrook Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$4.67 - $7.28 $2,428 - $3,785	520 New	520 $2,000
Q4 2023 Jan 31, 2024	BUY	$6.25 - $11.11 $556 - $988	89 Added 64.49%	227 $2,000
Q3 2023 Oct 25, 2023	SELL	$6.92 - $9.31 $13 - $18	-2 Reduced 1.43%	138 $1,000
Q2 2023 Jul 28, 2023	SELL	$6.36 - $11.47 $222 - $401	-35 Reduced 20.0%	140 $1,000
Q1 2023 Apr 26, 2023	SELL	$7.03 - $11.53 $499 - $818	-71 Reduced 28.86%	175 $1,000
Q4 2022 Jan 24, 2023	BUY	$8.32 - $13.21 $2,046 - $3,249	246 New	246 $0
Q3 2022 Nov 10, 2022	SELL	$12.16 - $19.42 $364 - $582	-30 Closed	0 $0
Q2 2022 Aug 01, 2022	SELL	$9.99 - $21.35 $1,078 - $2,305	-108 Reduced 78.26%	30 $0
Q1 2022 Apr 21, 2022	SELL	$14.08 - $27.63 $4,632 - $9,090	-329 Reduced 70.45%	138 $3,000
Q4 2021 Jan 18, 2022	BUY	$26.55 - $40.57 $11,602 - $17,729	437 Added 1456.67%	467 $12,000
Q4 2019 Jan 27, 2020	SELL	$19.49 - $32.63 $1,754 - $2,936	-90 Reduced 75.0%	30 $1,000
Q4 2018 Feb 07, 2019	BUY	$18.19 - $31.79 $2,182 - $3,814	120 New	120 $2,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.